

December 3, 1968

Dr. Peter E. Siegler, M.D.  
The National Drug Company  
Haines and McCallum Streets  
Philadelphia, Pennsylvania 19144

Dear Dr. Siegler:

Enclosed is a draft protocol for the study of aletamine. It is divided into three parts, which are successive approximations of the analysis of the problem.

The initial EEG trials are designed to test the dose and time relations of a single dose as it affects the EEG profile. These trials provide the basis for the definitive classification trials which are comparative with known standards. As soon as the classification is defined with surety, a clinical study can be designed and undertaken in the appropriate population.

While this procedure may be greater than the conventional open or double-blind clinical trial, it has some distinct advantages in providing the conventional data as well as the theoretically significant neurophysiological profile.

I will be pleased to have you visit once again to discuss these proposals in greater detail and wish to thank you for the opportunity to read this interesting material.

Sincerely yours,

Max Fink, M.D.  
Professor of Psychiatry

MF:kp